September 8, 2020
Audience: Health Professional, Pharmacy
September 8, 2020 — FDA is alerting health care professionals, oncology clinical investigators, and patients that a clinical trial studying the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) showed the drug combination did not work to treat the disease.
Atezolizumab in combination with paclitaxel is not approved for use in breast cancer. However, atezolizumab in combination with paclitaxel protein-bound (Abraxane)—a different combination therapy—is currently approved for the treatment of adult patients with mTNBC whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test. Continued approval of atezolizumab in combination with paclitaxel protein-bound may be contingent on proven benefit of the treatment in additional trials.
Health care professionals should not replace paclitaxel protein-bound (Abraxane) with paclitaxel in clinical practice.
The trial, IMpassion131, was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of atezolizumab in combination with paclitaxel compared with placebo and paclitaxel for patients with mTNBC.
In this clinical trial, treatment with atezolizumab and paclitaxel did not significantly reduce the risk of cancer progression and death compared with placebo and paclitaxel in the PD-L1-positive population. Additionally, interim overall survival results favored paclitaxel + placebo, over paclitaxel + atezolizumab in both the PD-L1-positive population and total population.
FDA will review the findings of IMpassion131 and will communicate new information regarding the IMpassion131 results and any potential changes to prescribing information. FDA is also evaluating the use of atezolizumab and paclitaxel in ongoing clinical trials for breast cancer and will recommend additional changes as appropriate.
Patients taking atezolizumab and paclitaxel for other approved uses should continue to take their medication as directed by their health care professional.
Patients should talk to their doctor if they have questions or concerns. Health care professionals and patients should report any adverse events or side effects related to the use of these products and other similar products to FDA’s MedWatch Adverse Event Reporting program.
- Complete and submit the report online; or
- Download and complete the form, then submit it via fax at 1-800-FDA-0178.
Tecentriq Prescribing Information
Source: FDA
Related Post
Feb
10 Health Benefits of Eating Eggs for Breakfast
Might it be said that you are fed up with having exactly the same thing for breakfast consistently? Does your morning meal leave you feeling hungry simply a brief time frame after you eat? Then eating a couple of eggs.
Read MoreFeb
Study Reveals Extent of Undiagnosed Cancer Cases Due to COVID-19 Pandemic
North of 134,000 disease cases went undiscovered in the U.S. during the initial 10 months of the Coronavirus pandemic, as per another College of Kentucky Markey Disease Center review. The report distributed in JAMA Oncology gives the principal assessments of.
Read MoreFeb
Another COVID Toll: Over 134,000 Undiagnosed Cancers During Height of Pandemic
In excess of 134,000 diseases could have gone undiscovered during the initial 10 months of the Coronavirus pandemic, as per an investigation of public patterns in malignant growth rate. Yearly disease occurrence fell practically 30% shy of the normal rate from.
Read MoreFeb
Top 10 Health Benefits of Eucalyptus
Eucalyptus is an evergreen tree local to Australia. Throughout the long term, eucalyptus leaves and oils have been consumed and made into prescription for different medical issue for people all over the planet. During the eighteenth and nineteenth hundreds of.
Read More